1)Collaborative Normal-Tension Glaucoma Study Group:The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126:498-505, 1998
2)The AGIS Investigators:The Advanced Glaucoma Intervention Study(AGIS):7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:429-440, 2000
3)日本緑内障学会:緑内障診療ガイドライン(第3版).日眼会誌 116:3-46,2012
4)Djafari F, Lesk MR, Harasymowycz PJ et al:Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma 18:238-242, 2009
5)Costa VP, Moreira H, Paolera MD et al:Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy. Clin Ophthalmol 6:699-706, 2012
6)Pfeiffer N, Scherzer ML, Maier H et al:Safety and efficacy of changing to the travoprost/timolol maleate fixed combination(DuoTrav)from prior mono- or adjunctive therapy. Clin Ophthalmol 4:459-466, 2010
7)Mandic Z, Novak-Lauš L, Bojic L et al:Observational study of patients switched to the fixed travoprost 0.004%/timolol 0.5% combination in Croatia. Methods Find Exp Clin Pharmacol 32:593-598, 2010
8)Kashiwagi K:Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy. Jpn J Ophthalmol 56:339-345, 2012
9)Kanamoto T, Kiuchi Y, Ichioka I et al:Clinical efficacy and travoprost-timolol fixed combination on ocular hypotensive agents and ocular surface agents in Japanese glaucoma patients. J Jpn Ophthalmol Soc 117:793-798, 2013
10)Inoue K, Setogawa A, Higa R et al:Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs. Clin Ophthalmol 6:231-235, 2012
11)Hughes BA, Bacharach J, Craven R et al:A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 14:392-399, 2005
12)Schuman JS, Katz GJ, Lewis RA et al:Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 140:242-250, 2005
13)Gross RL, Sullivan EK, Wells DT et al:Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%. Clin Ophthalmol 1:317-322, 2007
14)Gandolfi SA, Cimino L:Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 110:609-614, 2003
15)Williams RD:Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 19:275-281, 2002
16)Sato S, Hirooka K, Baba T et al:Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. J Ocul Pharmacol Ther 27:499-502, 2011
17)Sonty S, Donthamsetti V, Vangipuram G et al:Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost. J Ocul Pharmacol Ther 24:517-520, 2008